Nerve Growth Factor: Structure, Function and Therapeutic Implications for Alzheimers Disease
The DOI matches its Crossref record.
Abstract
Over the past decade, neurotrophic factors have generated much excitement for their potential as therapy for neurological disorders. In this regard, nerve growth factor (NGF), the founding member of the neurotrophin family, has generated great interest as a potential target for the treatment of Alzheimer's disease (AD). This interest is based on the observation that cholinergic basal forebrain (CBF) neurons which provide the major source of cholinergic innervation to the cerebral cortex and hippocampus undergo selective and severe degeneration in advanced AD and that these neurons are dependent upon NGF and its receptors for their survival. In fact, NGF transduces its effects by binding two classes of cell surface receptors, TrkA and p75(NTR), both of which are produced by CBF neurons. This review focuses on NGF/receptor binding, signal transduction, regulation of specific cellular endpoints, and the potential use of NGF in AD. Alterations in NGF ligand and receptor expression at different stages of AD are summarized. Recent results suggest that cognitive deficits in early AD and mild cognitive impairment (MCI) are not associated with a cholinergic deficit. Thus, the earliest cognitive deficits in AD may involve brain changes other than simply cholinergic system dysfunction. Recent findings indicate an early defect in NGF receptor expression in CBF neurons; therefore treatments aimed at facilitating NGF actions may prove highly beneficial in counteracting the cholinergic dysfunction found in end-stage AD and attenuating the rate of degeneration of these cholinergic neurons.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Endocytic mechanisms for targeted drug delivery☆
BAREFORD, L., & SWAAN, P. (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.06.008 · Cited by 1,033
Cholinergic system during the progression of Alzheimer’s disease: therapeutic implications
Mufson, E. J., Counts, S. E., Perez, S. E., & Ginsberg, S. D. (2008) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.8.11.1703 · Cited by 587
Self-citationUbhi, K., Rockenstein, E., Mante, M., Inglis, C., Adame, A., Patrick, C., Whitney, K., & Masliah, E. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.0567-10.2010 · Cited by 147
“…2009), and many studies have looked at NTF replacement strategies in an effort to stave of neuronal dysfunction and death in these disorders with a number reporting beneficial effects (Lad et al., 2003; Peterson and Nutt, 2008; Ramaswamy et al., 2009; Sadan et al., 2009; Saragovi et al., 2009).”
BackgroundCholinotrophic basal forebrain system alterations in 3xTg-AD transgenic mice
Perez, S. E., He, B., Muhammad, N., Oh, K.-J., Fahnestock, M., Ikonomovic, M. D., & Mufson, E. J. (2011) · Neurobiology of Disease · doi:10.1016/j.nbd.2010.10.002 · Cited by 80
“These receptors are produced in CBF neurons and transported to their projection sites (Lad et al., 2003; Sobreviela et al., 1994).”
BackgroundSelf-citation(2013) · PubMed · Cited by 21
Metadata
- Authors
- Lad, S., Neet, K., & Mufson, E.
- Venue
- Current Drug Target -CNS & Neurological Disorders
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2003-10-01
- Volume
- 2
- Issue
- 5
- Pages
- 315-334
- ISSN
- 1568-007X (ISSN-L)
- OpenAlex
- W2077340556
- Cited by
- 127
- References
- 0
- FWCI
- 6.70
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Nerve Growth Factor: Structure, Function and Therapeutic Implications for Alzheimers Disease. https://app.cochat.ai/papers/10.2174/1568007033482724
- The paper
- Lad, S., Neet, K., & Mufson, E. (2003). Nerve Growth Factor: Structure, Function and Therapeutic Implications for Alzheimers Disease. Current Drug Target -CNS & Neurological Disorders. https://doi.org/10.2174/1568007033482724
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.